

Pancreatic mucinous cystadenocarcinoma in a patient harbouring



ALL

IMAGES

VIDEOS

97 Results

Any time ▾

(PDF) Demographic, clinical, and pathological features of ...

https://www.researchgate.net/publication/327604838_Demographic_clinical_and...

Olaparib was recently approved by the US Food and Drug Administration for maintenance therapy in **germline BRCA1/2** mutated PDAC following demonstration of survival benefit in a phase 3 trial.

BRCA mutation frequency and clinical features of ovarian ...

https://www.researchgate.net/publication/335182721_BRCA_mutation_frequency_and...

A total of 153 EOC **patients** were found to carry pathogenic **germline mutations** in **BRCA1/2**, accounting for an overall **mutation** incidence of 16.7% with the predominance in **BRCA1** (13.1%) compared with ...

Pancreatic Cancer | Request PDF

https://www.researchgate.net/publication/51172656_Pancreatic_Cancer

Methods: **Pancreas** cancer **patients** with a **germline** pathogenic variant in **BRCA1/2** or other DDR gene were identified retrospectively through review of ...

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish ...

https://www.researchgate.net/publication/12576066_BRCA1_and_BRCA2_mutation_analysis_of...

A total of 153 EOC **patients** were found to carry pathogenic **germline mutations** in **BRCA1/2**, accounting for an overall **mutation** incidence of 16.7% with the predominance in **BRCA1** (13.1%) compared with ...

Genetic, Immunohistochemical, and Clinical Features of ...

https://www.researchgate.net/publication/12524450_Genetic_Immunohistochemical_and...

The survival of **patients** with wild-type KRAS and TP53 tumors was more than twice longer than that of **patients** bearing KRAS and TP53 **mutations** (90.2 vs. 41.1 months). **Patients**

国内版

国际版

Microsoft Bing

Pancreatic mucinous cystadenocarcinoma in a patient harbouring E

ALL

IMAGES

VIDEOS

226 Results

Any time

(PDF) Demographic, clinical, and pathological features of ...

https://www.researchgate.net/publication/327604838_Demographic_clinical_and...

Olaparib was recently approved by the US Food and Drug Administration for maintenance therapy in germline BRCA1/2 mutated PDAC following demonstration of survival benefit in a phase 3 trial.

US Patent Application for KUB5/HERA AS A DETERMINANT OF ...

https://patents.justia.com/patent/20180057888

Thus, in accordance with the present disclosure, there is provided a method of treating a cancer patient determined to (a) express low/undetectable levels of Kub-5-Hera (K-H), (b) have reduced K-H gene copy number relative to a normal cell, and/or (c) have a loss/reduction of function mutation in a K-H coding region, such as mutation in a K-H ...

Pancreatic Cancer | Request PDF

https://www.researchgate.net/publication/51172656_Pancreatic_Cancer

Methods: Pancreas cancer patients with a germline pathogenic variant in BRCA1/2 or other DDR gene were identified retrospectively through review of medical records (medical genetics/oncology) and ...

Intraductal papillary-mucinous neoplasia of the pancreas ...

https://www.researchgate.net/publication/49685868...

Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas is a clinically and morphologically distinctive precursor lesion of pancreatic cancer, characterized by gradual progression through a ...

Author: Caroline Verbeke

BRCA mutation frequency and clinical features of ovarian ...

https://www.researchgate.net/publication/335182721...

Download Citation | BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group | Aim: Subjects with germline BRCA1/2 mutations (gBRCAm) have an ...

The contribution of the hereditary nonpolyposis colorectal ...

https://www.researchgate.net/publication/7410507...

An enhanced response rate was also seen in patients harbouring only the BRCA1 SNP rs1799950, predicted to be detrimental to BRCA1 function (50%, 3 of 6 patients versus 12.1%, 7 of 58 patients; p ...

Abstracts | SpringerLink

https://link.springer.com/10.1007/s00428-018-2422-1

Aug 17, 2018 · In general patients harboring these gene fusions account for <3% of cancer population; however, they have been seen in over 40 histologies, including gastrointestinal, lung, head & neck, and sarcoma. In this presentation, we report on the occurrence of TRK, ROS1, and ALK fusions in patients treated in Cancer Center Institute of Oncology.

96. Jahrestagung der DGP 2012 - Verhandlungsband 7.1 MB ...

doczz.net/doc/5812187/96.-jahrestagung-der-dgp...

Translate this page

Brune K, Abe T, Canto M et al (2006) Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol 30:1067–1076 7. Campman SC, Fajardo MA, Rippon MB et al (1997) Adenosquamous carcinoma arising in a mucinous cystadenoma of the pancreas.

Molecular and Clinical Oncology - Spandidos Publications

https://www.spandidos-publications.com/mco/articlesbydate.jsp

Molecular and Clinical Oncology is a monthly medical journal in the field of oncology that covers a wide range of original research, while offering a rapid publication process. The articles comprising each issue are carefully selected, peer-reviewed and revised to provide a wide variety of high-quality scientific research. Articles published in Molecular and Clinical Oncology are listed in ...

US Patent for LOX and LOXL2 inhibitors and uses thereof ...

https://patents.justia.com/patent/9176139

The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an ...

Some results are removed in response to a notice of local law requirement. For more information, please see here.

1

2

3

4

5

>

Chat with Bing

Eh, I seem to know why you query this.

Say something...

Search Tools

Turn off Hover Translation (关闭取词)

增值电信业务经营许可证：合字82-20090007

京ICP备10036305号

京公网安备11010802022657号

Privacy and Cookies

Legal

Advertise

Help

© 2020 Microsoft

Feedback

Match Overview

1	Internet 106 words crawled on 27-Apr-2020 www.wjnet.com	5%
2	Crossref 100 words Doulamis, Ilias P., Konstantinos S. Mylonas, Christos E. K alfountzos, Danny Mou, Huzaifa Haj-Ibrahim, and Dimitrio	4%
3	Internet 60 words www.ncbi.nlm.nih.gov	3%
4	Internet 50 words crawled on 25-Nov-2016 pdfs.semanticscholar.org	2%
5	Internet 37 words crawled on 06-May-2020 www.nejm.org	2%
6	Internet 25 words crawled on 27-Oct-2019 t6publishing.blob.core.windows.net	1%
7	Crossref 23 words "Annual Congress of the European Association of Nuclear Medicine October 13 – 17, 2018 Düsseldorf, Germany", ...	1%
8	Crossref 19 words Y-H Bai, C-C Ren, X-R Gong, L-P Meng. "A maternal here ditary deafness pedigree of the A1555G mitochondrial n ...	1%

6
Name of Journal: *World Journal of Gastrointestinal Oncology*

Manuscript NO: 60052

Manuscript Type: CASE REPORT

**Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline
mutation effectively treated with olaparib: A case report**

Di Marco M *et al.* Pancreatic mucinous cystadenocarcinoma treated with olaparib

1
Mariacristina Di Marco, Riccardo Carloni, Stefania De Lorenzo, Cristina Mosconi,
Andrea Palloni, Elisa Grassi, Daria Maria Filippini, Angela Dalia Ricci, Alessandro
Rizzo, Alessandro Di Federico, Donatella Santini, Daniela Turchetti, Claudio Ricci,
Carlo Ingaldi, Laura Alberici, Francesco Minni, Rita Golfieri, Giovanni Brandi, Riccardo
Casadei

2
Abstract

BACKGROUND

Pancreatic mucinous cystadenocarcinoma in a patient harbouring BI



ALL

IMAGES

VIDEOS

221 Results

Any time ▾

US Patent Application for KUB5/HERA AS A DETERMINANT ...

<https://patents.justia.com/patent/20180057888> ▾

Thus, in accordance with the present disclosure, there is provided a method of treating a cancer **patient** determined to (a) express low/undetectable levels of Kub-5-Hera (K-H), (b) have reduced K-H gene copy number relative to a normal cell, and/or (c) have a loss/reduction of function **mutation** in a K-H coding region, such as **mutation** in a K-H ...

Intraductal papillary-mucinous neoplasia of the pancreas ...

<https://www.researchgate.net/publication/49685868>...

Intraductal papillary-mucinous neoplasm (IPMN) of the **pancreas** is a clinically and morphologically distinctive precursor lesion of **pancreatic cancer**, characterized by gradual progression through a ...

Author: Caroline Verbeke

Pancreatic Cancer | Request PDF

https://www.researchgate.net/publication/51172656_Pancreatic_Cancer

Methods: **Pancreas cancer patients** with a **germline** pathogenic variant in BRCA1/2 or other DDR gene were identified retrospectively through review of medical records (medical genetics/oncology) and ...

BRCA mutation frequency and clinical features of ovarian ...

<https://www.researchgate.net/publication/335182721>...

Download Citation | BRCA **mutation** frequency and clinical features of ovarian cancer **patients**: A report from a Chinese study group | Aim: Subjects with **germline** BRCA1/2 **mutations** (gBRCAm) have an ...

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi ...

<https://www.researchgate.net/publication/12576066>...

A total of 153 EOC **patients** were found to carry pathogenic **germline** **mutations** in BRCA1/2, accounting for an overall **mutation** incidence of 16.7% with the predominance in BRCA1 ...

Genetic, Immunohistochemical, and Clinical Features of ...

<https://www.researchgate.net/publication/12524450>...

The survival of **patients** with wild-type KRAS and TP53 tumors was more than twice longer than that of **patients** bearing KRAS and TP53 **mutations** (90.2 vs. 41.1 months). **Patients** with KRAS wild-type ...